Bipolar disorders treatment market analysis | Coherent Market Insights

1. Coherent Marketing Insights https://www.coherentmarketinsights.com/ Market Research & Business Consulting Services Covid-19 Impact Tracker

2. BIPOLAR DISORDERS TREATMENT MARKET ANALYSIS Bipolar Disorder Treatment Market, By Drug Class (Antipsychotics, Antidepressants, Mood Stabilizers, and Anti-anxiety Drugs and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

3. Bipolar disorder, also known as manic illness, is a brain disorder that affects the mood, energy level, and other activities. This disorder consists of various episodes, and major among these are – manic and depression. There is a sudden change in mood of the patient and his/her ability to carry out daily tasks. There are four types of bipolar disorders: bipolar I, bipolar II, cyclothymic, and other specified and non-specified bipolar and related disorders. The people suffering from bipolar disorder experience periods of unusually intense emotion, irregular sleep patterns and activity levels, and mood episodes. Bipolar disorder is diagnosed based on the patient’s symptoms, family history, and lifetime history. The healthcare provider generally conducts a mental health evaluation for the diagnosis of bipolar disorder. The global bipolar disorder treatment market size is estimated to be valued at US$ 7,288.3 million in 2019 and is expected to exhibit a CAGR of 5.2% over the forecast period (2019-2027).

4. Figure 1. Global Bipolar Disorder Treatment Market Value (US$ Mn), by Region, 2019

5. Increasing product approvals and launches are expected to propel the market growth over the forecast period Key players are focusing on enhancing their product portfolio through increasing launches and approvals of new drugs for the treatment of bipolar disorder, which is expected to drive growth of the bipolar disorder treatment market over the forecast period. For instance, in May 2019, Allergan plc and Gedeon Richter Plc. received the U.S. Food and Drug Administration (FDA) approval for its supplemental new drug application (sNDA) of VRAYLAR (cariprazine), anoral, once daily atypical antipsychotic drug for expanded use and treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults. Moreover, in May 2016, Procera Health announced the launch of ProceraMood, a non-prescription drug, which offers mood stabilization, and supporting balance and calmness.

6. Figure 2. Global Bipolar Disorder Treatment Market Share (%), by Drug Class, 2019 and 2027

7. Increasing mergers, agreements, and collaborations to develop treatment for bipolar disorder is expected to drive the market growth over the forecast period Market players are focused on adoption of inorganic growth strategies such as collaborations and partnerships to strengthen their position in the bipolar disorder treatment market. For instance, in November 2017, Sumitomo Dainippon Pharma Co., Ltd and Angelini S.p.A entered into a strategic partnership in order to distribute and commercialize Latuda (Lurasidone Hydrochloride), developed by Sumitomo Dainippon Pharma, in the European market (29 European countries and in Turkey). Under this agreement, a subsidiary company of Sumitomo Dainippon Pharma Group (Sunovion Pharmaceuticals Europe Ltd.) granted rights to Angelini for distribution and commercialization of LATUDA in European Market. However, side effects associated with drugs used in the treatment of bipolar disorder is expected to be a factor negatively affecting growth of the market up to certain extent, as patients hesitate to undergo medication therapy due to fear of the same. For instance, some of the medications including carbamazepine, Divalproex sodium, and Lithium used in the treatment of bipolar disorder have some side effects such as nausea, tremors, sexual problem, impaired memory, muscle weakness, decreased thyroid function, liver and kidney damage, skin reactions, and others.

8. Key Players Major players operating in the global bipolar disorder treatment market include Takeda Pharmaceutical Company Limited, Pfizer, Inc., Allergan plc, Otsuka Holdings Co. Ltd., Johnson & Johnson, Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca Plc, Novartis International AG, AbbVie Inc., H. Lundbeck A/S, Minerva Neurosciences, Sumitomo Dainippon Pharma Co., Ltd., Intra-Cellular Therapies Inc., Gedeon Richter Plc., and Indivior PLC.

9. Request Sample Report Request Customization Download PDF Brochure Talk to Analyst Referance: https://www.coherentmarketinsights.com/market-insight/bipolar-disorders-treatment-market-2605

10. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. What We Provide:Customized Market Research AnalysisIndustry Analysis ServicesBusiness Consulting ServicesLong Term Engagement ModelCountry Specific Analysis

11. Contact Us Mr. Shah Coherent Market Insights Pvt. LTD.Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154, U.S.Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

12. Thank You Kindly Follow CMI Social Media Profiles for the latest Company Updates. Facebook Linkedin Twitter https://www.coherentmarketinsights.com/